An unusual etiology of torsade de pointes-induced syncope.

作者信息

Morosin Marco, Dametto Ermanno, Bianco Federica Del, Brieda Marco, Nicolosi Gian L

机构信息

Cardiovascular Department "Ospedali Riuniti" Trieste and Postgraduate School Cardiovascular Sciences, University of Trieste and Cardiology Department "Santa Maria degli Angeli" Hospital, Pordenone, Italy.

Cardiology Department, ARC. "Santa Maria degli Angeli" Hospital, Pordenone, Italy.

出版信息

Arch Med Sci. 2017 Apr 1;13(3):686-688. doi: 10.5114/aoms.2017.67287. Epub 2017 Apr 20.

DOI:10.5114/aoms.2017.67287

PMID:28507587

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5420640/

Abstract

摘要

相似文献

An unusual etiology of torsade de pointes-induced syncope.

Arch Med Sci. 2017 Apr 1;13(3):686-688. doi: 10.5114/aoms.2017.67287. Epub 2017 Apr 20.

Familial inducible torsade de pointes with normal QT interval.

Eur Heart J. 1983 Jun;4(6):383-90. doi: 10.1093/oxfordjournals.eurheartj.a061484.

Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.

Ann Intern Med. 1989 Oct 1;111(7):574-80. doi: 10.7326/0003-4819-111-7-574.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Can J Cardiol. 1997 Apr;13(4):383-6.

Haloperidol-induced torsade de pointes.

Ann Pharmacother. 1999 Oct;33(10):1046-50. doi: 10.1345/aph.19017.

[CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].

Praxis (Bern 1994). 2020 Sep;109(12):944-951. doi: 10.1024/1661-8157/a003583.

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports.

Glob Cardiol Sci Pract. 2017 Jun 30;2017(2):11. doi: 10.21542/gcsp.2017.11.

Torsade de pointes in a case of pheochromocytoma--an unusual presentation of an uncommon disease.

Indian Heart J. 2004 May-Jun;56(3):248-9.

Torsade de pointes associated with the combination of solifenacin and clenbuterol for urinary incontinence.

J Cardiol Cases. 2013 Dec 12;9(3):91-93. doi: 10.1016/j.jccase.2013.10.009. eCollection 2014 Mar.

Mode of onset of torsade de pointes in congenital long QT syndrome.

J Am Coll Cardiol. 1996 Nov 1;28(5):1262-8. doi: 10.1016/s0735-1097(96)00311-7.

引用本文的文献

Rhabdomyolysis in a male adolescent associated with monotherapy of fluvoxamine.

Eur J Hosp Pharm. 2023 Sep;30(5):302-304. doi: 10.1136/ejhpharm-2022-003533. Epub 2022 Dec 2.

Catecholaminergic polymorphic ventricular tachycardia due to RyR2 mutation: recreational cycling as a trigger of lethal arrhythmias.

Arch Med Sci. 2019 Nov 12;16(2):466-470. doi: 10.5114/aoms.2019.89691. eCollection 2020.

本文引用的文献

Wearable sensors in syncope management.

Med Sci Monit. 2015 Jan 22;21:276-82. doi: 10.12659/MSM.892147.

Association of corrected QT interval with long-term mortality in patients with syncope.

Arch Med Sci. 2013 Dec 30;9(6):1049-54. doi: 10.5114/aoms.2013.39383. Epub 2013 Dec 5.

Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.

Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31.

Age-and sex-dependent mRNA expression of KCNQ1 and HERG in patients with long QT syndrome type 1 and 2.

Arch Med Sci. 2011 Dec 31;7(6):941-7. doi: 10.5114/aoms.2011.26604. Epub 2011 Dec 30.

QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Dtsch Arztebl Int. 2011 Oct;108(41):687-93. doi: 10.3238/arztebl.2011.0687. Epub 2011 Oct 14.

Clinical impact of fluvoxamine-mediated long QTU syndrome.

Eur J Clin Pharmacol. 2012 Jan;68(1):109-11. doi: 10.1007/s00228-011-1091-7. Epub 2011 Jun 29.

Psychotropic drugs associated with corrected QT interval prolongation.

J Clin Psychopharmacol. 2009 Feb;29(1):9-15. doi: 10.1097/JCP.0b013e318191c6a8.

Drug-induced torsades de pointes: the evolving role of pharmacogenetics.

Heart Rhythm. 2005 Nov;2(2 Suppl):S30-7. doi: 10.1016/j.hrthm.2005.08.007.

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Br J Pharmacol. 2003 Jul;139(5):887-98. doi: 10.1038/sj.bjp.0705335.

Adverse drug reactions: definitions, diagnosis, and management.

Lancet. 2000 Oct 7;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

An unusual etiology of torsade de pointes-induced syncope.

Arch Med Sci. 2017 Apr 1;13(3):686-688. doi: 10.5114/aoms.2017.67287. Epub 2017 Apr 20.

Familial inducible torsade de pointes with normal QT interval.

Eur Heart J. 1983 Jun;4(6):383-90. doi: 10.1093/oxfordjournals.eurheartj.a061484.

Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy.

Ann Intern Med. 1989 Oct 1;111(7):574-80. doi: 10.7326/0003-4819-111-7-574.

Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.

Can J Cardiol. 1997 Apr;13(4):383-6.

Haloperidol-induced torsade de pointes.

Ann Pharmacother. 1999 Oct;33(10):1046-50. doi: 10.1345/aph.19017.

[CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].

Praxis (Bern 1994). 2020 Sep;109(12):944-951. doi: 10.1024/1661-8157/a003583.

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports.

Glob Cardiol Sci Pract. 2017 Jun 30;2017(2):11. doi: 10.21542/gcsp.2017.11.

Torsade de pointes in a case of pheochromocytoma--an unusual presentation of an uncommon disease.

Indian Heart J. 2004 May-Jun;56(3):248-9.

Torsade de pointes associated with the combination of solifenacin and clenbuterol for urinary incontinence.

J Cardiol Cases. 2013 Dec 12;9(3):91-93. doi: 10.1016/j.jccase.2013.10.009. eCollection 2014 Mar.

Mode of onset of torsade de pointes in congenital long QT syndrome.

J Am Coll Cardiol. 1996 Nov 1;28(5):1262-8. doi: 10.1016/s0735-1097(96)00311-7.

引用本文的文献

Rhabdomyolysis in a male adolescent associated with monotherapy of fluvoxamine.

Eur J Hosp Pharm. 2023 Sep;30(5):302-304. doi: 10.1136/ejhpharm-2022-003533. Epub 2022 Dec 2.

Catecholaminergic polymorphic ventricular tachycardia due to RyR2 mutation: recreational cycling as a trigger of lethal arrhythmias.

Arch Med Sci. 2019 Nov 12;16(2):466-470. doi: 10.5114/aoms.2019.89691. eCollection 2020.

本文引用的文献

Wearable sensors in syncope management.

Med Sci Monit. 2015 Jan 22;21:276-82. doi: 10.12659/MSM.892147.

Association of corrected QT interval with long-term mortality in patients with syncope.

Arch Med Sci. 2013 Dec 30;9(6):1049-54. doi: 10.5114/aoms.2013.39383. Epub 2013 Dec 5.

Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.

Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31.

Age-and sex-dependent mRNA expression of KCNQ1 and HERG in patients with long QT syndrome type 1 and 2.

Arch Med Sci. 2011 Dec 31;7(6):941-7. doi: 10.5114/aoms.2011.26604. Epub 2011 Dec 30.

QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Dtsch Arztebl Int. 2011 Oct;108(41):687-93. doi: 10.3238/arztebl.2011.0687. Epub 2011 Oct 14.

Clinical impact of fluvoxamine-mediated long QTU syndrome.

Eur J Clin Pharmacol. 2012 Jan;68(1):109-11. doi: 10.1007/s00228-011-1091-7. Epub 2011 Jun 29.

Psychotropic drugs associated with corrected QT interval prolongation.

J Clin Psychopharmacol. 2009 Feb;29(1):9-15. doi: 10.1097/JCP.0b013e318191c6a8.

Drug-induced torsades de pointes: the evolving role of pharmacogenetics.

Heart Rhythm. 2005 Nov;2(2 Suppl):S30-7. doi: 10.1016/j.hrthm.2005.08.007.

Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Br J Pharmacol. 2003 Jul;139(5):887-98. doi: 10.1038/sj.bjp.0705335.

Adverse drug reactions: definitions, diagnosis, and management.

Lancet. 2000 Oct 7;356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9.